Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Indocyanine Green
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Recipient : University of Alabama at Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parathyroid Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Indocyanine Green
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Recipient : University of Alabama at Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indocyanine Green
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomach Ulcer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : Indocyanine Green
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indocyanine Green
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Kurt Weiss
Deal Size : Inapplicable
Deal Type : Inapplicable
Fluorescent Intra-operative Tumor Margin Examination
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Indocyanine Green
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Kurt Weiss
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Virginia Commonwealth University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Postoperative Cognitive Complications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2019
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Virginia Commonwealth University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Angela Bianco
Deal Size : Inapplicable
Deal Type : Inapplicable
Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor
Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Surgical Wound Infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2018
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Angela Bianco
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : University of Texas Health Science Center at Houston
Deal Size : Inapplicable
Deal Type : Inapplicable
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Stroke.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 28, 2017
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : University of Texas Health Science Center at Houston
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IC2000 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 27, 2017
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Vanderbilt University
Deal Size : Inapplicable
Deal Type : Inapplicable
2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients
Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Surgical Wound Infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 07, 2015
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Vanderbilt University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indocyanine Green
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cholecystitis, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2014
Lead Product(s) : Indocyanine Green
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bone Morphogenetic Protein-7
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bone Morphogenetic Protein-7 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 31, 2010
Lead Product(s) : Bone Morphogenetic Protein-7
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
